Analyzing Ligand Pharmaceuticals (LGND) and ANI Pharmaceuticals (ANIP)

Ligand Pharmaceuticals (NASDAQ: LGND) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Risk & Volatility

Ligand Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 2.9, meaning that its share price is 190% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Ligand Pharmaceuticals and ANI Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals 1 0 4 0 2.60
ANI Pharmaceuticals 0 1 2 0 2.67

Ligand Pharmaceuticals presently has a consensus target price of $147.80, indicating a potential downside of 0.10%. ANI Pharmaceuticals has a consensus target price of $71.00, indicating a potential downside of 0.08%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Valuation & Earnings

This table compares Ligand Pharmaceuticals and ANI Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ligand Pharmaceuticals $108.97 million 28.65 -$1.63 million $0.69 214.42
ANI Pharmaceuticals $128.62 million 6.44 $3.93 million $0.63 112.79

ANI Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

55.1% of ANI Pharmaceuticals shares are owned by institutional investors. 8.3% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 31.8% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Ligand Pharmaceuticals and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals 12.76% 7.83% 4.64%
ANI Pharmaceuticals 4.45% 22.40% 11.14%

Summary

ANI Pharmaceuticals beats Ligand Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply